sacrosidase
SUCRAID (sacrosidase). Approved for congenital sucrase-isomaltase deficiency. First approved in 1998.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
SUCRAID (sacrosidase) is an oral enzyme replacement therapy approved in 1998 for the treatment of congenital sucrase-isomaltase deficiency. The medication is formulated as an oral solution containing sacrosidase, a sucrose-specific enzyme that breaks down sucrose into glucose and fructose in the small intestine. It addresses a rare genetic condition where patients lack sufficient endogenous enzyme activity to digest sucrose, enabling improved nutrient absorption and symptom relief.
Sucrose-specific Enzyme
Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSUCRAID currently has zero open positions linked in available job tracking data, reflecting the product's mature, niche market position. Career opportunities would primarily exist in specialty pharmaceutical sales, medical affairs, and marketing roles focused on orphan disease management and gastroenterology specialist engagement. Success in roles supporting this product requires expertise in rare disease marketing, patient advocacy relationships, and management of declining-revenue-stage pharmaceutical products.